Navigation Links
Quintessence Secures Financing

MADISON, WI. - Quintessence Biosciences, Inc., a biotechnology company developing pharmaceutical products for use in research, has finalized a three million dollar financing deal. The majority of the funding, $2.3 million, was received from individual investors, and the remainder was borrowed from the Madison Development Corporation, Wisconsin Department of Commerce, and m2 Lease Funds, a private ......

Full article >>> as received, it has been placed in the exciting position of entering the marketplace with highly sought new tools for protein research.

One of the projects of Quintessence Biosciences is the formulation of multivalent drugs. Multivalent drugs are a new class of medications able to attach to pathogens with several binding sites, enabling them to be precise enough tools to treat a wide va......

Full article >>> ged cartilage or ligaments. Also, collagen is also required for the healing of wounds; products using synthetic collagen could assist in wound treatment.

"Its worth noting that both Quintessence and Nutra-Park, which also announced a round of financing last Thursday, were presenters at the November 2002 Wisconsin Life Sciences Venture Conference sponsored by the Wisconsin Technology Coun......

Full article >>>
'"/>

Source:wistechnology.com By Jamie Lyn Hofmeister 05/28/03


Related biology technology :

1. Quintessence Biosciences advances cancer drug
2. Quintessence Biosciences names new president
3. Quintessence cancer treatment chosen for clinical studies
4. Quintessence division to develop drug tests with NIH grant
5. Quintessence Biosciences forms cancer therapeutic advisory board
6. nPoint Secures Second Round of Funding
7. Financing life science: The ongoing saga
8. Financing of biotech companies so far in 2005: A Midwest odyssey
9. Seed-Stage Venture Financing
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... the release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” ... and retention in this eBook by providing practical tips, tools, and strategies for ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
(Date:6/23/2016)... ... 23, 2016 , ... Charm Sciences, Inc. is pleased to ... AOAC Research Institute approval 061601. , “This is another AOAC-RI approval of the ... Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods perform comparably ...
Breaking Biology Technology:
(Date:6/22/2016)... , June 22, 2016  The American College of ... Trade Show Executive Magazine as one of the fastest-growing ... May 25-27 at the Bellagio in Las Vegas ... the highest percentage of growth in each of the following ... exhibiting companies and number of attendees. The 2015 ACMG Annual ...
(Date:6/21/2016)... , June 21, 2016 NuData ... the new role of principal product architect and ... the director of customer development. Both will report ... technical officer. The moves reflect NuData,s strategic growth ... response to high customer demand and customer focus ...
(Date:6/15/2016)... June 15, 2016 Transparency ... titled "Gesture Recognition Market by Application Market - Global Industry Analysis ... 2024". According to the report, the  global gesture recognition ... 2015 and is estimated to grow at a ... by 2024.  Increasing application of gesture ...
Breaking Biology News(10 mins):